Medical marijuana can soothe nausea and increase appetite, quiet pain, soothe anxiety and even reduce epileptic seizures. Other research on the healing effects of cannabis is being examined. For example, research suggests that THC may be able to improve memory according to a 2016 study on mice. More than half of the United States has legalized marijuana for medical use.
A large, retrospective cohort study of 64,855 men aged 15 to 49 years from the United States found that Cannabis use was not associated with tobacco-related cancers and a number of other common malignancies. However, the study did find that, among nonsmokers of tobacco, ever having used Cannabis was associated with an increased risk of prostate cancer.[6]
No, as long as the plant is used correctly then no it’s not a bad thing. I’m sure there’s probably more good capability about that plant that people know or don’t know. No matter how it’s administered, as long as used properly it’s a good thing. It probably has more healing capabilities than people know about and since big Pharma or whoever it is out there discovered this, that’s probably why they made it illegal for all we know. Yes, I know there’s no money in cure which would hurt big Pharma but oh well! If they want to keep us away from the cure and keep us all sick, I say go for it anyway and go for the cure.
Until recent times, the cultivation of hemp primarily as an oilseed was largely unknown, except in Russia. Today, it is difficult to reconstruct the type of plant that was grown there as an oilseed, because such cultivation has essentially been abandoned. Oilseed hemp cultivars in the modern sense were not available until very recently, but some land races certainly were grown specifically for seeds in Russia. Dewey (1914) gave the following information: “The short oil-seed hemp with slender stems, about 30 inches high, bearing compact clusters of seeds and maturing in 60 to 90 days, is of little value for fiber production, but the experimental plants, grown from seed imported from Russia, indicate that it may be valuable as an oil-seed crop to be harvested and threshed in the same manner as oil-seed flax.” Most hemp oilseed in Europe is currently obtained from so-called “dual usage” plants (employed for harvest of both stem fiber and seeds, from the same plants). Of the European dual-usage cultivars, ‘Uniko B’ and ‘Fasamo’ are particularly suited to being grown as oilseeds. Very recently, cultivars have been bred specifically for oilseed production. These include ‘Finola,’ formerly known as ‘Fin-314’ (Fig. 6) and ‘Anka’ (Fig. 7), which are relatively short, little-branched, mature early in north-temperate regions, and are ideal for high-density planting and harvest with conventional equipment. Dewey (1914) noted that a Turkish narcotic type of land race called “Smyrna” was commonly used in the early 20th century in the US to produce birdseed, because (like most narcotic types of Cannabis) it is densely branched, producing many flowers, hence seeds. While oilseed land races in northern Russia would have been short, early-maturing plants in view of the short growing season, in more southern areas oilseed landraces likely had moderate height, and were spaced more widely to allow abundant branching and seed production to develop. Until Canada replaced China in 1998 as a source of imported seeds for the US, most seeds used for various purposes in the US were sterilized and imported from China. Indeed, China remains the largest producer of hempseed. We have grown Chinese hemp land races, and these were short, branched, adapted to a very long growing season (i.e. they come into flower very slowly in response to photoperiodic induction of short days in the fall), and altogether they were rather reminiscent of Dewey’s description of Smyrna. Although similar in appearance to narcotic strains of C. sativa, the Chinese land races we grew were in fact low in intoxicating constituents, and it may well be that what Dewey thought was a narcotic strain was not. Although some forms of C. sativa have quite large seeds, until recently oilseed forms appear to have been mainly selected for a heavy yield of seeds, usually recognizable by abundant branching. Such forms are typically grown at lower densities than hemp grown only for fiber, as this promotes branching, although it should be understood that the genetic propensity for branching has been selected. Percentage or quality of oil in the seeds does not appear to have been important in the past, although selection for these traits is now being conducted. Most significantly, modern selection is occurring with regard to mechanized harvesting, particularly the ability to grow in high density as single-headed stalks with very short branches bearing considerable seed.
There is a general inverse relationship in the resin of Cannabis between the amounts of THC present and the amount of the other principal cannabinoid, CBD. Whereas most drug strains contain primarily THC and little or no CBD, fiber and oilseed strains primarily contain CBD and very little THC. CBD can be converted to THC by acid catalyzed cyclization, and so could serve as a starting material for manufacturing THC. In theory, therefore, low-THC cultivars do not completely solve the problem of drug abuse potential. In practice, however, the illicit drug trade has access to easier methods of synthesizing THC or its analogues than by first extracting CBD from non-drug hemp strains.

Scientists in Europe and North America concluded that hemp seed is an excellent source of nutrition. Numerous anecdotal incidences cited improvements in a wide range of acute and chronic conditions such as rapid healing of skin lesions and relief from flu, inflammation, and allergies. The benefits were attributed to the presence of rich source of the EFAs linoleic and alpha-linolenic acid, and their respective biologic metabolites, GLA and stearidonic acid.9

A short-term Advisory Board has been appointed to serve through the development of the rules and regulations. The rules and regulations themselves will identify the guidelines for formation of the Advisory Board, so upon adoption of the rules and regulations an Advisory Board will be created which will continue on a regular basis beyond that point.

One systematic review studied 30 randomized comparisons of delta-9-THC preparations with placebo or other antiemetics from which data on efficacy and harm were available.[31] Oral nabilone, oral dronabinol, and intramuscular levonantradol (a synthetic analog of dronabinol) were tested. Inhaled Cannabis trials were not included. Among all 1,366 patients included in the review, cannabinoids were found to be more effective than the conventional antiemetics prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, and alizapride. Cannabinoids, however, were not more effective for patients receiving very low or very high emetogenic chemotherapy. Side effects included a feeling of being high, euphoria, sedation or drowsiness, dizziness, dysphoria or depression, hallucinations, paranoia, and hypotension.[31]

To this point, CBD oil has existed in a kind of liminal space— at once an illegal drug, a legal medication, and some kind of “dietary” supplement. It’s possible this could change in the coming years, however. GW Pharmaceuticals, a U.K.-based firm, has developed a “pure CBD” medication called Epidiolex that has shown promising test results. It is currently on a fast-track to receive FDA clearance. For some patients, Epidiolex could be a miracle cure. This summer, in Wired magazine, writer Fred Vogelstein chronicled his family’s own struggles to find an effective treatment for his son’s epilepsy—including experiments with hemp oil— and the immense hurdles they overcame to gain access to Epidiolex prior to its FDA approval. The drug could be for sale on pharmacy shelves in the near future, though exactly how near is hard to say.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy,[13] Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use.[14] This change applies only to FDA-approved products containing no more than 0.1 percent THC.[14] This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs.[14] Epidiolex still requires rescheduling in some states before it can be prescribed in those states.[66][67]
Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids.[61] Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. Non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-9 tetrahydrocannabinol concentration of no more than three-tenths of one percent (0.3%) on a dry weight basis.[62] Certain standards are required for legal growing, cultivating and producing the hemp plant. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the THC concentration does not exceed 0.3% on a dry weight basis.[62]
Jews living in Palestine in the 2nd century were familiar with the cultivation of hemp, as witnessed by a reference to it in the Mishna (Kil'ayim 2:5) as a variety of plant, along with Arum, that sometimes takes as many as three years to grow from a seedling. In late medieval Germany and Italy, hemp was employed in cooked dishes, as filling in pies and tortes, or boiled in a soup.[109] Hemp in later Europe was mainly cultivated for its fibers, and was used for ropes on many ships, including those of Christopher Columbus. The use of hemp as a cloth was centered largely in the countryside, with higher quality textiles being available in the towns.

"The data supporting efficacy and dosing are specific to one product: Epidiolex," Bonn-Miller says. "That's not necessarily translatable to 'Joe Bob's CBD Blend.'" A CBD extract you buy online or in a dispensary will almost certainly have less CBD in it, he explains, and will contain other cannabinoids—meaning that it will work differently and will need to be dosed differently. "This is not to say that 'Joe Bob's CBD Blend' definitely isn't going to be effective for pediatric epilepsy, but it means that we need to study it before we know."

Right now, there’s a good chance that you don’t really know what you’re getting from any source. Testing and labeling rules vary by state, but many states that allow legal cannabis also require some kind of testing to verify that the THC and CBD levels listed on the label are accurate. However, this testing is controversial, and results can vary widely between labs, Jikomes said. A study published in March found measurable variations in test results, with some labs consistently reporting higher or lower levels of cannabinoids than others. There are no guarantees that the label accurately reflects what’s in the product. For a 2015 study published in JAMA, researchers tested 75 products purchased in San Francisco, Los Angeles and Seattle and found that only 17 percent were accurately labeled. More than half of the products contained significantly lower levels of cannabinoids than the label promised, and some of them contained only negligible amounts of the compounds. “We need to come up with ways to confidently verify the composition of cannabis products and make this information available to consumers,” Jikomes said.
The objectivity of scientific evaluation of the medicinal value of marijuana to date has been questioned. In the words of Hirst et al. (1998): “The ...status of cannabis has made modern clinical research almost impossible. This is primarily because of the legal, ethical and bureaucratic difficulties in conducting trials with patients. Additionally, the general attitude towards cannabis, in which it is seen only as a drug of abuse and addiction, has not helped.” In a recent editorial, the respected journal Nature (2001) stated: “Governments, including the US federal government, have until recently refused to sanction the medical use of marijuana, and have also done what they can to prevent its clinical testing. They have defended their inaction by claiming that either step would signal to the public a softening of the so-called ‘war on drugs.’... The pharmacology of cannabinoids is a valid field of scientific investigation. Pharmacologists have the tools and the methodologies to realize its considerable potential, provided the political climate permits them to do so.” Given these current demands for research on medicinal marijuana, it will be necessary to produce crops of drug types of C. sativa.
Taking CBD oil is like drinking milk and calling it calcium, Hernandez said: There’s some in there, but at very low concentrations dispersed among a host of other ingredients. And what those other ingredients are is anyone’s guess. “The thing to know is that CBD hasn’t gone through the safety controls, the efficacy controls that we usually use, the clinical trials,” Hernandez said. “The jury is still out regarding how safe this drug is.”
Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
In the Australian states of Tasmania, Victoria, Queensland, and most recently, New South Wales, the state governments have issued licences to grow hemp for industrial use. The first to initiate modern research into the potential of cannabis was the state of Tasmania, which pioneered the licensing of hemp during the early 1990s. The state of Victoria was an early adopter in 1998, and has reissued the regulation in 2008.[71]
Short-term use of the drug impairs thinking and coordination. In long-term studies, teens who smoke marijuana have lower IQs later on, as well as structural differences in their brains, though scientists debate whether this is an effect of the drug or a result of habitual pot smokers seeking out less intellectually stimulating pursuits. A 2016 study on almost 300 students by the University of Montreal published in the journal Development and Psychopathology found that teens who start smoking around age 14 do worse on some cognitive tests by age 20 than non-smokers. They also have a higher school dropout rate. If they wait until age 17 to start, though, the smokers do not seem to have the same impairments, according to the study.
There are practical, if cruder alternatives to separate the long fiber for high-quality textile production, but in fact such techniques are used mostly for non-textile applications. This involves production of “whole fibers” (i.e. harvesting both the long fibers from the cortex and the shorter fibers from throughout the stem), and technologies that utilize shortened hemp fibers. This approach is currently dominant in western Europe and Canada, and commences with field dew retting (typically 2–3 weeks). A principal limitation is climatic—the local environment should be suitably but not excessively moist at the close of the harvest season. Once stalks are retted, dried, and baled, they are processed to extract the fiber. In traditional hemp processing, the long fiber was separated from the internal woody hurds in two steps, breaking (stalks were crushed under rollers that broke the woody core into short pieces, some of which were separated) and scutching (the remaining hurds, short fibers (“tow”) and long fibers (“line fiber, ” “long-line fiber”) were separated). A single, relatively expensive machine called a decorticator can do these two steps as one. In general in the EU and Canada, fibers are not separated into tow and line fibers, but are left as “whole fiber.” In western Europe, the fiber is often “cottonized,” i.e. chopped into short segments the size of cotton and flax fiber, so that the fibers can be processed on flax processing machinery, which is very much better developed than such machinery is for hemp. In North America the use of hemp for production of even crude textiles is marginal. Accordingly, the chief current fiber usages of North American, indeed of European hemp, are non-textile.
In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act. This Act imposed a levy of $1 per ounce for medicinal use of Cannabis and $100 per ounce for nonmedical use. Physicians in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for prescribing Cannabis, use special order forms to procure it, and keep special records concerning its professional use. In addition, the AMA believed that objective evidence that Cannabis was harmful was lacking and that passage of the Act would impede further research into its medicinal worth.[6] In 1942, Cannabis was removed from the U.S. Pharmacopoeia because of persistent concerns about its potential to cause harm.[2,3]
My dad has severe advanced stage Dementia. Will CBD oil help him at this point? He is now refusing to eat any solid food, but will accept most drinks.In addition, he has lost a great deal of weight even though they're giving him Mega Shakes containing a full meals worth of proteins, etc. He gets at least 4 of these a day..some which he refuses. Is his Dementia too far gone for CBD oils to help him?

Despite advances in pharmacologic and nonpharmacologic management, nausea and vomiting (N/V) remain distressing side effects for cancer patients and their families. Dronabinol, a synthetically produced delta-9-THC, was approved in the United States in 1986 as an antiemetic to be used in cancer chemotherapy. Nabilone, a synthetic derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States.[24] Both dronabinol and nabilone have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of N/V associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapy. Numerous clinical trials and meta-analyses have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.[25-28] The National Comprehensive Cancer Network Guidelines recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V.[29] The American Society for Clinical Oncology (ASCO) antiemetic guidelines updated in 2017 recommends that the FDA-approved cannabinoids, dronabinol or nabilone, be used to treat N/V that is resistant to standard antiemetic therapies.[30]

Of the 20 known amino acids, hemp supplies them all, including the essential ones the body can’t produce, known as EAAs. About 65 percent of the protein in hemp seeds is edestin, a globulin protein that aids in digestion, similar to the globulin found in human blood plasma, and hemp seeds are the only place they’re found. The other third is made up of the protein albumin.
A large, retrospective cohort study of 64,855 men aged 15 to 49 years from the United States found that Cannabis use was not associated with tobacco-related cancers and a number of other common malignancies. However, the study did find that, among nonsmokers of tobacco, ever having used Cannabis was associated with an increased risk of prostate cancer.[6]
Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.
Acute effects may include anxiety and panic, impaired attention, and memory (while intoxicated), an increased risk of psychotic symptoms, and possibly an increased risk of accidents if a person drives a motor vehicle while intoxicated.[68] Short-term cannabis intoxication can hinder the mental processes of organizing and collecting thoughts. This condition is known as temporal disintegration.[69] Psychotic episodes are well-documented and typically resolve within minutes or hours. There have been few reports of symptoms lasting longer.[70][71]
Did you get an answer for this? I have the exact same scenario. I'm treating my TN with Tegretol, and recently tried CBD. I think I took too much and there are some weird drug interactions with Tegretol and I felt quite stoned....was alone and talking to myself in my head thinking I was Einstein. It freaked me out a bit but I think I took too much. I'm trying lower doses again as recently my TN seems to be resisting the meds, although I have had a lot of emotional stress, which seems to be a trigger. Thanks!! Anna